<DOC>
	<DOCNO>NCT02431728</DOCNO>
	<brief_summary>Individuals recover drug and/or alcohol addiction initially experience symptom acute withdrawal experience symptom post-acute withdrawal ( PAWS ) . PAWS include wide array emotional psychological symptom anxiety , sleep disturbance , depression , stress . Previous study show melatonin therapy beneficial alleviate anxiety , depressive symptom , sleep disturbance . However , randomize , double-blind , placebo control trial conduct male experience PAWS . The purpose study investigate effect 5 mg melatonin give nightly four week weekly assess , self-reported anxiety , depressive symptom , insomnia , stress male PAWS reside residential treatment center .</brief_summary>
	<brief_title>The Effect Melatonin Upon Post-Acute Withdrawal Among Males Residential Treatment Program</brief_title>
	<detailed_description>Approval obtain Institutional Review Board Duquesne University prior study implementation . The trial single-center , randomize , double-blind , match placebo-controlled , parallel-group trial conduct male 18 year age older residential treatment program chemical dependency Salvation Army Harbor Light Center ( 865 West North Avenue , Pittsburgh , Pennsylvania , 15233 ) United States America . Convenience sample use recruit individual July 2015 December 2015 . A total sample 70 participant enrol block randomize allocation ratio 1:1 intervention . Financial compensation $ 5.00 U.S. initiate Day 7 continue follow-up ( Day 14 , Day 21 &amp; Day 28 ) . Intention-to-treat complete case analysis conduct . No interim analysis perform assess efficacy . Participants complete study material designate room center . Briefly , study involve completion four validate survey assess self-reported perceived severity anxiety ( Generalized Anxiety Disorder Scale ; GAD-7 ) , depression ( Personal Health Questionnaire Depression Scale ; PHQ-8 ) , stress ( Perceived Stress Scale ; PSS-14 ) , sleep complaint sleep affect daily life ( Pittsburgh Sleep Symptom Questionnaire - Insomnia ; PSSQ-1 ) five time point ( Baseline , Day 7 , Day 14 , Day 21 , Day 28 ) . To address adverse event relate intervention , participant encourage report perceive adverse event investigator . To protect anonymity confidentiality participant , paperwork de-identified contain unique identification number .</detailed_description>
	<mesh_term>Substance Withdrawal Syndrome</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Males 18 year age older actively participate therapy residential treatment program Willingness participate 4week study Willingness provide selfreported demographic , social , medical , medication , preventive , mental health history Willingness complete selfassessments anxiety , depression , insomnia , stress designate time interval Willingness administer daily bed capsule contain either 5 mg melatonin plus vegetable fiber filler vegetable fiber filler without melatonin ( i.e. , match placebo ) . English speaking Patients already take melatonin Adverse history melatonin supplementation</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Melatonin</keyword>
	<keyword>Post-acute withdrawal symptom</keyword>
	<keyword>Anxiety</keyword>
	<keyword>Depression</keyword>
	<keyword>Insomnia</keyword>
	<keyword>Stress</keyword>
	<keyword>Substance withdrawal syndrome</keyword>
</DOC>